WINDLAS BIOTEACH LTD -IPO Review

​By a Staff Reporter: WINDLAS BIOTECH LTD - IPO Review

Windlas Biotech Ltd is amongst the top five players in the domestic pharmaceutical formulations contract development and manufacturing organization (“CDMO”) industry in India in terms of revenue (Source: CRISIL Report). With over two decades of experience in manufacturing both solid and liquid pharmaceutical dosage forms and significant experience in providing specialized capabilities, including, high potency, controlled substances and low solubility, it provide a comprehensive range of CDMO services ranging from product discovery, product development, licensing and commercial manufacturing of generic products, including complex generics, in compliance with current Good Manufacturing Practices (“GMP”) with a focus on improved safety, efficacy and cost. Company’s Promoter, and Whole-time Director, Ashok Kumar Windlass, has over 20 years of experience in the manufacturing and pharmaceutical business in India, while Hitesh Windlass Promoter and Managing Director, helped with regards to the strategic, corporate and technical operations.

Post issue Promoter shareholding will be 65.16%

Source : Eureka

Open Demat and Trading Account online please visit https://kyc.eurekasecurities.net/home/index/729​

or please call us at 9831200699